Advances in Head and Neck Surgery
By M. Steele Brown, special assignment to Bulletin From preemptive strikes against pharyngeal cancers to advances in robotic surgery, Otolaryngology—Head and Neck Surgery is riding a wave of trends and technological discoveries toward significant breakthroughs. Jay O. Boyle, MD, chair of the Head and Neck Surgery section of the AAO—HNSF Centralized Otolaryngology Research Efforts (CORE) program, said one example of this is how the specialty is fighting head and neck squamous cell cancer on several fronts—and winning. “Our knowledge is expanding, and with that in mind, researchers are continually able to generate new and more exciting hypotheses,” Dr. Boyle said. “In addition to the research in the lab, technology is beginning to allow us to answer questions more completely and faster than previously possible, due to the continuing advances in molecular biology and the discovery of high-throughput ways in which we can analyze many tumors in a short period of time. In addition, the sequencing of the human genome—specifically the head and neck cancer genome, offers us quite a bit of insight into head and neck cancers, as well as a better understanding of other common issues, such as melanoma. We’ve also seen lots of good research in the area of salivary gland cancers.” Battling Cancer Many of the most important surgical breakthroughs occur before surgery is even necessary. Nowhere is this more true than in the realm of oncology. Head and neck cancer is the sixth-most common non-skin cancer in the world with more than half a million new cases each year. According to research from the National Cancer Institute (NCI), smokers, drinkers, and people infected with the human papillomavirus (HPV) have the highest risk of developing cancer in the oral cavity. Because of that, stopping these issues before they take root is an imperative. Dr. Boyle, also an associate attending physician in Head and Neck Surgery at Memorial Sloan-Kettering Cancer Center and associate professor of otolaryngology, Weill Medical College of Cornell University in New York, said the increased understanding of tobacco addiction is one key to fighting cancer. “In addition, smoking cessation research is also advancing,” he said. “I think I speak for all head and neck surgeons when I say that I’m hoping that this research will help the effectiveness of the cessation programs that are out there right now. As awareness regarding the dangers of tobacco increases and smoking rates continue decreasing, this will have a positive influence on future head and neck cancer rates.” Marion E. Couch, MD, PhD, associate professor in the Department of Otolaryngology/Head and Neck Surgery at Fletcher Allen Health Care, said that on the public health front, the recent recommendation from the Centers for Disease Control and Prevention (CDC)—that boys and young men up to the age of 21 be vaccinated against HPV—is “huge for the field.” “From our point of view, this is a real victory because simply vaccinating young girls will not solve the problem,” Dr. Couch said. “We are leaving the other half of the population at risk. “While we are still looking for more and better data, there is evidence to suggest that HPV could be responsible for many cases of oral cancer—most of which occur in men. So I am greatly relieved that both boys and girls will now be vaccinated against HPV.” While the latest expansion of the indications for the HPV vaccine is not for head and neck cancer, Dr. Couch believes that evidence will inevitably come to light. “In the meantime, we will have to work to remove barriers in this regard,” she said. “But the news of the latest expansion is still welcome and will help us in our fight.” Dr. Boyle said he concurred with Dr. Couch regarding HPV’s connection to head and neck cancer, and added that while the evidence of the connection is anecdotal, he believes it is a real concern. “Some of the most important advances we have made are due to the fact that many of the cancers that we are finding in the pharynx now, we will find are caused by HPV,” he said. “The good thing about that is these particular cancers have a high cure rate—higher than 90 percent—and are amenable to cancer prevention, so from a curative standpoint, this is all new and exciting territory for head and neck surgeons.” Further Research In addition to the believed connection with HPV, Dr. Boyle said more encouraging advances exist in the realm of genomics. “As the field (of genomics) evolves during the next five to 10 years, we will be able to individualize therapy for cancer,” he said. “And as we learn more about the molecular biology of tumors and tumor-host interactions, as well as how cancers are inherited, we will be able to better tailor treatment to the specific biology that is going on with the particular cancer. It is a good bet that this promising advance in head and neck oncology will be available to us in the next five to 10 years.” As researchers make headway in understanding the process of carcinogenesis, Dr. Boyle said they are also getting closer to identifying a way to reverse that process in the upper air tract using medications. “For example, I am involved in ongoing randomized trials with a cancer prevention drug used to treat precancerous lesions of the mouth,” he said. “That study is open in nine institutions in the United States and one in Italy. That is an example of bench-to-bedside research where a hypothesis from the lab, and the subsequent animal studies, may create a drug that is useful in preventing oral cancer by targeting leukoplakia.” Dr. Boyle was also quick to note that science should not be a substitute for cessation. “We are not here to make smoking safer,” he said. “We need to stay focused on cessation and cessation research, but those patients who do quit still remain at moderate risk, and they are the ones we need to help with these therapies. We need to be able to halt and reverse cancer formation in patients who are successful in quitting.” As the chair of CORE, Dr. Boyle said it is also important to note that new research is constantly coming to the attention of the Academy. “The number of head and neck oncology research proposals is increasing and the quality is improving as well,” he said. “There are lots of exciting ideas and they are coming to our attention in many different areas of cancer biology.” Educating on Robotic Surgery Headway is also being made as the number of otolaryngologic surgeons training in robotic procedures continues to grow, Dr. Couch said. “We could soon be looking at equivalent cure rates for robotic interventions and chemoradiation therapy,” he said. “That said, I think we are seeing the pendulum swing back to the surgical approach for many of these diseases, and our patients are demanding outcomes using these innovative techniques.” Dr. Boyle echoed that idea and said that transoral robotic surgery (TORS) has become a significant recent development. And while it is not yet proven to have the same cure rates as radiation therapy, it is likely to be proven in the next year or so. At this point, he said, the problem is with the number of trials. “There are not any direct head-to-head random trials because we cannot randomize surgical patients,” he said. “But the data we do have says the cure rates are good.” “So as TORS becomes more common in the coming five- to 10-year span, we can, and probably will, see a lowering in the intensity of radiation therapy necessary after surgery. That will be good for our patients.” Dennis H. Kraus, MD, the chair of Head and Neck Education for the Academy, added that robotic thyroidectomy is also helping head and neck surgeons advance the specialty. “With robotic thyroidectomy, we can avoid making incisions in the neck,” Dr. Kraus said. “It really seems to be catching on and it offers a lot of advantages, such as an approach under the arm and one behind the ear, for example. “I think there is a real focus on minimizing the effect of surgery on the patient right now. We are able to be just as effective, but in a way in which we do not hurt the patient, and that is an attractive path.” These developments, taken together, multiply the medical and surgical knowledge available exponentially, Dr. Couch said. “All of this has allowed us to embrace innovation, which is exciting for our field,” she said. “But it is also right in time because we are under pressure to treat patients who are getting younger because of HPV. Our patients used to be 60 to 80 years old, but now they are getting younger and are demanding excellent outcomes in terms of survival.”
By M. Steele Brown, special assignment to Bulletin
From preemptive strikes against pharyngeal cancers to advances in robotic surgery, Otolaryngology—Head and Neck Surgery is riding a wave of trends and technological discoveries toward significant breakthroughs.
Jay O. Boyle, MD, chair of the Head and Neck Surgery section of the AAO—HNSF Centralized Otolaryngology Research Efforts (CORE) program, said one example of this is how the specialty is fighting head and neck squamous cell cancer on several fronts—and winning.
“Our knowledge is expanding, and with that in mind, researchers are continually able to generate new and more exciting hypotheses,” Dr. Boyle said. “In addition to the research in the lab, technology is beginning to allow us to answer questions more completely and faster than previously possible, due to the continuing advances in molecular biology and the discovery of high-throughput ways in which we can analyze many tumors in a short period of time.
In addition, the sequencing of the human genome—specifically the head and neck cancer genome, offers us quite a bit of insight into head and neck cancers, as well as a better understanding of other common issues, such as melanoma. We’ve also seen lots of good research in the area of salivary gland cancers.”
Battling Cancer
Many of the most important surgical breakthroughs occur before surgery is even necessary. Nowhere is this more true than in the realm of oncology.
Head and neck cancer is the sixth-most common non-skin cancer in the world with more than half a million new cases each year. According to research from the National Cancer Institute (NCI), smokers, drinkers, and people infected with the human papillomavirus (HPV) have the highest risk of developing cancer in the oral cavity. Because of that, stopping these issues before they take root is an imperative.
Dr. Boyle, also an associate attending physician in Head and Neck Surgery at Memorial Sloan-Kettering Cancer Center and associate professor of otolaryngology, Weill Medical College of Cornell University in New York, said the increased understanding of tobacco addiction is one key to fighting cancer.
“In addition, smoking cessation research is also advancing,” he said. “I think I speak for all head and neck surgeons when I say that I’m hoping that this research will help the effectiveness of the cessation programs that are out there right now. As awareness regarding the dangers of tobacco increases and smoking rates continue decreasing, this will have a positive influence on future head and neck cancer rates.”
Marion E. Couch, MD, PhD, associate professor in the Department of Otolaryngology/Head and Neck Surgery at Fletcher Allen Health Care, said that on the public health front, the recent recommendation from the Centers for Disease Control and Prevention (CDC)—that boys and young men up to the age of 21 be vaccinated against HPV—is “huge for the field.”
“From our point of view, this is a real victory because simply vaccinating young girls will not solve the problem,” Dr. Couch said. “We are leaving the other half of the population at risk.
“While we are still looking for more and better data, there is evidence to suggest that HPV could be responsible for many cases of oral cancer—most of which occur in men. So I am greatly relieved that both boys and girls will now be vaccinated against HPV.”
While the latest expansion of the indications for the HPV vaccine is not for head and neck cancer, Dr. Couch believes that evidence will inevitably come to light.
“In the meantime, we will have to work to remove barriers in this regard,” she said. “But the news of the latest expansion is still welcome and will help us in our fight.”
Dr. Boyle said he concurred with Dr. Couch regarding HPV’s connection to head and neck cancer, and added that while the evidence of the connection is anecdotal, he believes it is a real concern.
“Some of the most important advances we have made are due to the fact that many of the cancers that we are finding in the pharynx now, we will find are caused by HPV,” he said. “The good thing about that is these particular cancers have a high cure rate—higher than 90 percent—and are amenable to cancer prevention, so from a curative standpoint, this is all new and exciting territory for head and neck surgeons.”
Further Research
In addition to the believed connection with HPV, Dr. Boyle said more encouraging advances exist in the realm of genomics.
“As the field (of genomics) evolves during the next five to 10 years, we will be able to individualize therapy for cancer,” he said. “And as we learn more about the molecular biology of tumors and tumor-host interactions, as well as how cancers are inherited, we will be able to better tailor treatment to the specific biology that is going on with the particular cancer. It is a good bet that this promising advance in head and neck oncology will be available to us in the next five to 10 years.”
As researchers make headway in understanding the process of carcinogenesis, Dr. Boyle said they are also getting closer to identifying a way to reverse that process in the upper air tract using medications.
“For example, I am involved in ongoing randomized trials with a cancer prevention drug used to treat precancerous lesions of the mouth,” he said. “That study is open in nine institutions in the United States and one in Italy. That is an example of bench-to-bedside research where a hypothesis from the lab, and the subsequent animal studies, may create a drug that is useful in preventing oral cancer by targeting leukoplakia.”
Dr. Boyle was also quick to note that science should not be a substitute for cessation.
“We are not here to make smoking safer,” he said. “We need to stay focused on cessation and cessation research, but those patients who do quit still remain at moderate risk, and they are the ones we need to help with these therapies. We need to be able to halt and reverse cancer formation in patients who are successful in quitting.”
As the chair of CORE, Dr. Boyle said it is also important to note that new research is constantly coming to the attention of the Academy.
“The number of head and neck oncology research proposals is increasing and the quality is improving as well,” he said. “There are lots of exciting ideas and they are coming to our attention in many different areas of cancer biology.”
Educating on Robotic Surgery
Headway is also being made as the number of otolaryngologic surgeons training in robotic procedures continues to grow, Dr. Couch said.
“We could soon be looking at equivalent cure rates for robotic interventions and chemoradiation therapy,” he said. “That said, I think we are seeing the pendulum swing back to the surgical approach for many of these diseases, and our patients are demanding outcomes using these innovative techniques.”
Dr. Boyle echoed that idea and said that transoral robotic surgery (TORS) has become a significant recent development. And while it is not yet proven to have the same cure rates as radiation therapy, it is likely to be proven in the next year or so. At this point, he said, the problem is with the number of trials.
“There are not any direct head-to-head random trials because we cannot randomize surgical patients,” he said. “But the data we do have says the cure rates are good.”
“So as TORS becomes more common in the coming five- to 10-year span, we can, and probably will, see a lowering in the intensity of radiation therapy necessary after surgery. That will be good for our patients.”
Dennis H. Kraus, MD, the chair of Head and Neck Education for the Academy, added that robotic thyroidectomy is also helping head and neck surgeons advance the specialty.
“With robotic thyroidectomy, we can avoid making incisions in the neck,” Dr. Kraus said. “It really seems to be catching on and it offers a lot of advantages, such as an approach under the arm and one behind the ear, for example.
“I think there is a real focus on minimizing the effect of surgery on the patient right now. We are able to be just as effective, but in a way in which we do not hurt the patient, and that is an attractive path.”
These developments, taken together, multiply the medical and surgical knowledge available exponentially, Dr. Couch said.
“All of this has allowed us to embrace innovation, which is exciting for our field,” she said. “But it is also right in time because we are under pressure to treat patients who are getting younger because of HPV. Our patients used to be 60 to 80 years old, but now they are getting younger and are demanding excellent outcomes in terms of survival.”